
|Videos|November 24, 2020
Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study
Advertisement
Episodes in this series

Advertisement
Related to this article

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.

Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.

A phase 2a crossover trial testing low-dose and high-dose levetiracetam in early Alzheimer disease did not significantly improve global cognition versus placebo.

A real-world registry found that large infarct core size does not independently predict worse functional or safety outcomes after thrombectomy, compared with moderate-core infarcts.

Results from Eli Lilly's phase 2 PRESENCE-ALZ trial show the dopamine D1 receptor modulator missed its primary cognitive and functional goal in Alzheimer disease.

Phase 3 POLARIS-AD results show AR1001 benefit on CDR-SB in a prespecified monotherapy population, but not in the overall early Alzheimer disease population.

In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis
2
Mevidalen Misses Primary Endpoint in Phase 2 Alzheimer Trial
3
NeuroVoices: Brian Lin, PhD, on the FDA Approval of Gefurulimab for Generalized Myasthenia Gravis
4
Positioning B-Cell–Depleting Therapies in the MG Treatment Sequence
5















